IFP Advisors’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

IFP Advisors’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-817	Closed	-$269K	–	3374
2024 Q1	$269K	Sell	817 -3	-0.4%	-$952	0.01%	855
2023 Q4	$260K	Sell	820 -10	-1%	-$1.94K	0.01%	845
2023 Q3	$140K	Buy	830 +16	+2%	+$3.01K	0.01%	1125
2023 Q2	$177K	Sell	814 -13	-2%	-$2.79K	0.01%	1082
2023 Q1	$16.6K	Buy	827 +295	+55%	+$56.4K	﹤0.01%	2093
2022 Q4	$36K	Buy	532 +158	+42%	+$33.9K	﹤0.01%	2475
2022 Q3	$35K	Buy	+374	New	+$75.7K	﹤0.01%	2657
2021 Q2	–	Sell	-1,039	Closed	-$121K	–	3282
2021 Q1	$127K	Buy	1,039 +99	+11%	+$11.2K	﹤0.01%	1056
2020 Q4	$96K	Buy	940 +14	+2%	+$1.3K	﹤0.01%	1154
2020 Q3	$70K	Buy	+926	New	+$78.9K	﹤0.01%	1157

IFP Advisors's KRTX Position: Q2 2024 in Review

IFP Advisors sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2024, closing a stake of 817 shares — an estimated $269K sold.

IFP Advisors first reported a position in KRTX in Q3 2020 and held it in 10 quarters. The position peaked at $269K in Q1 2024. 0 funds tracked by Wall St. Rank hold KRTX as of Q2 2024.

IFP Advisors reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2024 after selling out during the quarter.
IFP Advisors sold 817 Karuna Therapeutics, Inc. Common Stock shares in Q2 2024, an estimated $269K.
IFP Advisors first reported a position in Karuna Therapeutics, Inc. Common Stock in Q3 2020 and held it in 10 quarters.
IFP Advisors's Karuna Therapeutics, Inc. Common Stock position peaked at $269K in Q1 2024.
0 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2024.

Based on IFP Advisors's 13F filing for Q2 2024, filed 30 Jul 2024.